Benzinga | Oct 12, 2021 08:02AM EDT

JMP Securities Maintains Market Outperform on Allogene Therapeutics, Lowers Price Target to $27

JMP Securities analyst Reni Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and lowers the price target from $53 to $27.